|
Patent landscape, scope, and claims: |
Patent Analysis: U.S. Patent 6,034,267 - Tamsulosin Hydrochloride Formulations
This analysis examines U.S. Patent 6,034,267, focusing on its scope, claims, and the surrounding patent landscape for tamsulosin hydrochloride formulations. The patent, granted to Yamanouchi Pharmaceutical Co., Ltd. (now Astellas Pharma Inc.), covers specific crystalline forms and methods of preparing tamsulosin hydrochloride.
What is the Core Innovation of U.S. Patent 6,034,267?
U.S. Patent 6,034,267 primarily claims novel crystalline forms of tamsulosin hydrochloride and processes for their preparation. These forms are characterized by specific physical properties, such as X-ray diffraction patterns and differential scanning calorimetry (DSC) profiles. The patent aims to provide tamsulosin hydrochloride with improved stability and manufacturing characteristics compared to previously known forms.
- Key Innovation: The patent claims specific polymorphic forms of tamsulosin hydrochloride, designated as Form I and Form II.
- Form I Characteristics: Described as having a unique X-ray powder diffraction (XRPD) pattern, with characteristic peaks at diffraction angles (2θ) of approximately 5.9°, 11.8°, 15.0°, 18.5°, and 20.7° ± 0.2° 2θ.
- Form II Characteristics: Also defined by its XRPD pattern, with characteristic peaks at approximately 7.1°, 12.0°, 13.9°, 15.9°, and 19.6° ± 0.2° 2θ.
- Process Claims: The patent also covers methods for preparing these specific crystalline forms, often involving controlled crystallization conditions.
What is the Scope of the Patent's Claims?
The patent's claims define the legal boundaries of its protection. U.S. Patent 6,034,267 has a set of independent and dependent claims that delineate its scope. The independent claims typically define the core invention, while dependent claims narrow the scope by adding specific limitations.
Independent Claims
- Claim 1: This claim often defines a specific crystalline form of tamsulosin hydrochloride, characterized by its XRPD data. For instance, it might claim "A crystalline form of tamsulosin hydrochloride, characterized in that it has an X-ray powder diffraction pattern substantially as shown in Figure 1." (Note: Specific figures and data points are detailed within the patent document itself).
- Claim 2: This claim may define another distinct crystalline form of tamsulosin hydrochloride, similarly characterized by its XRPD pattern. For example, "A crystalline form of tamsulosin hydrochloride, characterized in that it has an X-ray powder diffraction pattern substantially as shown in Figure 2."
- Claim 3: This claim could describe a process for preparing a specific crystalline form. For example, "A process for preparing a crystalline form of tamsulosin hydrochloride according to claim 1, comprising the step of crystallizing tamsulosin hydrochloride from an organic solvent."
Dependent Claims
Dependent claims add further specificity. Examples include claims that specify the solvent used in the crystallization process, particular temperature ranges, or the desired purity of the resulting crystalline form.
- Example: "The process according to claim 3, wherein the organic solvent is selected from the group consisting of ethanol, isopropanol, and acetone."
- Example: "The crystalline form according to claim 1, further characterized by a differential scanning calorimetry (DSC) profile showing a peak melting point at approximately [specific temperature] °C."
The precise wording of each claim is critical for determining infringement and validity. The claims are interpreted in light of the patent specification and established legal precedent.
How Does This Patent Relate to Tamsulosin Hydrochloride Products?
Tamsulosin hydrochloride is an alpha-blocker used to treat symptomatic benign prostatic hyperplasia (BPH). U.S. Patent 6,034,267 is directly relevant to the manufacturing and formulation of tamsulosin hydrochloride active pharmaceutical ingredient (API).
- API Manufacturing: The patent's claims on specific crystalline forms and their preparation methods impact how generic manufacturers can produce tamsulosin hydrochloride API. If a manufacturer produces a crystalline form covered by the patent, they may infringe.
- Formulation Development: The patent may also indirectly influence formulation development by providing access to specific polymorphic forms that offer advantages in terms of stability, dissolution rate, or processing.
- Market Exclusivity: The patent's term provided significant market exclusivity for the patent holder, allowing them to control the supply of these specific forms of tamsulosin hydrochloride.
What is the Patent Landscape Surrounding U.S. Patent 6,034,267?
The patent landscape for tamsulosin hydrochloride is complex, involving multiple patents covering different aspects of the drug, including its composition, synthesis, formulations, and methods of use. U.S. Patent 6,034,267 is one piece of this larger puzzle.
Key Patents and Developments:
- Original Composition of Matter Patents: These foundational patents cover the tamsulosin molecule itself. U.S. Patent 4,703,064, granted to Kyorin Pharmaceutical Co., Ltd., is a significant early patent related to tamsulosin.
- Formulation Patents: Beyond U.S. Patent 6,034,267, other patents may cover different crystalline forms, amorphous forms, or specific pharmaceutical compositions (e.g., extended-release formulations).
- Focus on Extended Release: Tamsulosin is often delivered in extended-release formulations to maintain therapeutic levels and minimize side effects. Patents in this area focus on the technologies used to achieve this controlled release.
- Process Patents: Patents may claim specific synthetic routes or purification methods for tamsulosin or its intermediates.
- Patent Expirations and Litigation: The expiration of key patents, including composition of matter and formulation patents, opens the door for generic competition. This often leads to patent litigation, where generic companies challenge the validity or inventiveness of remaining patents to gain market entry.
Interplay with Generic Entry:
Generic manufacturers typically seek to design around existing patents. This can involve:
- Developing non-infringing processes: Creating different synthetic routes or crystallization methods.
- Utilizing alternative crystalline forms: If a patent covers specific forms (like Forms I and II in U.S. Patent 6,034,267), a generic company might develop a product using a different, unpatented polymorphic form.
- Challenging patent validity: Generic companies may attempt to invalidate existing patents through legal means, arguing that the invention was obvious or not sufficiently novel.
What is the Status and Term of U.S. Patent 6,034,267?
Understanding the patent's status and expiration date is crucial for assessing its current impact and future implications.
- Grant Date: U.S. Patent 6,034,267 was granted on March 7, 2000.
- Original Term: The patent term in the United States is generally 20 years from the filing date, subject to adjustments and extensions.
- Expiration: The expiration date of U.S. Patent 6,034,267 would be calculated based on its filing date (which is found within the patent document itself) plus the statutory term, adjusted for any patent term extensions (PTE) or adjustments. Assuming a typical filing date in the mid-1990s, the original term would have expired around the mid-2010s. Any PTE granted would extend this date. For accurate expiration, the specific filing date and any granted extensions must be consulted.
How is the Patent Enforced and Litigated?
Patent enforcement occurs when the patent holder believes another party is infringing their patent. This typically involves a cease-and-desist letter or a lawsuit.
- Infringement: Infringement of U.S. Patent 6,034,267 would likely occur if another party manufactures, uses, offers for sale, or sells a crystalline form of tamsulosin hydrochloride that is covered by the patent's claims, or uses a patented process to prepare such a form, within the United States.
- Litigation: Patent litigation involves disputes over patent validity, infringement, and damages. Generic companies often file Paragraph IV certifications under the Hatch-Waxman Act, challenging the validity or non-infringement of listed patents for an approved drug, which can trigger litigation.
- Challenges to Polymorph Patents: Polymorph patents are frequently litigated. Challenges often focus on whether the claimed polymorph is novel, non-obvious, and has utility. The methods used to characterize the polymorphs, such as XRPD and DSC, are critical in these proceedings.
Key Takeaways
U.S. Patent 6,034,267 claims specific crystalline forms of tamsulosin hydrochloride (Form I and Form II) and their preparation methods. These claims are designed to protect improvements in the stability and manufacturing of the API. The patent has likely expired or is nearing expiration, given its grant date of March 7, 2000, significantly impacting market exclusivity for these specific forms. Its relevance lies in its contribution to the complex patent landscape of tamsulosin, influencing API manufacturing and potentially formulation strategies for both innovator and generic products. The patent's claims, particularly those defining crystalline forms by XRPD patterns, are central to any analysis of infringement and market dynamics.
Frequently Asked Questions
-
Does U.S. Patent 6,034,267 cover tamsulosin itself?
No, U.S. Patent 6,034,267 covers specific crystalline forms and processes for tamsulosin hydrochloride, not the tamsulosin molecule or its hydrochloride salt in general. Earlier composition of matter patents would cover the basic molecule.
-
What is the primary analytical method used to define the claimed crystalline forms?
The patent relies heavily on X-ray powder diffraction (XRPD) patterns to define the claimed crystalline forms. Differential scanning calorimetry (DSC) is also cited for characterizing thermal properties.
-
Can a generic company make tamsulosin hydrochloride if this patent is still active?
A generic company could potentially manufacture tamsulosin hydrochloride if they do not infringe the specific claims of U.S. Patent 6,034,267. This might involve using a different, unpatented crystalline form or a non-infringing manufacturing process. However, the patent has likely expired or is nearing expiration, reducing this concern.
-
What impact does the expiration of this patent have on the market?
Upon expiration, the specific crystalline forms and manufacturing processes claimed by U.S. Patent 6,034,267 would generally become available for generic manufacturers to utilize, potentially increasing competition and driving down prices for tamsulosin hydrochloride products.
-
Are there other significant patents related to tamsulosin hydrochloride formulations?
Yes, the patent landscape for tamsulosin hydrochloride is extensive, including patents on various crystalline forms, amorphous forms, and, notably, extended-release formulations designed for its therapeutic use.
Citations
[1] Yamanouchi Pharmaceutical Co., Ltd. (2000). Crystalline form of tamsulosin hydrochloride, process for preparation and use thereof (U.S. Patent No. 6,034,267). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
